{"entity":{"id":"nct06764875","kind":"trial","name":"A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer","aka":[],"tldr":"A phase 3 trial of Rilvegostomig, Trastuzumab deruxtecan, Trastuzumab, Pembrolizumab, Capecitabine and Cisplatin in gastric & gastro-oesophageal junction cancer, run by AstraZeneca, now recruiting.","summary":"A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer is a phase 3 interventional study registered as NCT06764875 by AstraZeneca, with 840 participants planned, started 2025-03-01 and due to reach its primary completion in 2029-04-27. Interventions recorded: Rilvegostomig, Trastuzumab deruxtecan, Trastuzumab, Pembrolizumab, 5-fluorouracil and Capecitabine.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06764875","url":"https://clinicaltrials.gov/study/NCT06764875"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":[],"drugs":["rilvegostomig","trastuzumab-deruxtecan","trastuzumab","pembrolizumab","capecitabine","cisplatin"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06764875","phase":"3","setting":"A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)","sponsor":"AstraZeneca","enrolled":840,"outcomes":[]},"route":"/trials/nct06764875/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"rilvegostomig","kind":"drug","name":"Rilvegostomig","route":"/drugs/rilvegostomig/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}